Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has been shown to induce apoptosis in neoplastic cells. While many previous studies have been performed in cell culture, the delivery and efficiency of TRAIL variants in vivo is less well established. Using dual substrate/ reporter bioluminescence imaging (Fluc: firefly luciferase -luciferin and Rluc: Renilla luciferase -coelenterazine), we tested the efficacy of TRAIL using replicationdeficient herpes simplex virus (HSV) type 1 amplicon vectors in gliomas. The cDNA for complete TRAIL and the extracellular domain of TRAIL (aa 114-281) were cloned into HSV amplicons and packaged into helper virus-free vectors. Both forms of TRAIL induced similar degrees of apoptosis in human glioma cells (Gli36) in culture within 24 h of infection with TRAIL amplicon vectors. Growth of tumors stably transfected with Fluc (Gli36fluc þ ) was readily monitored in vivo by bioluminescence imaging following luciferin administration. HSV amplicon vectors bearing the genes for TRAIL and Rluc injected directly into Gli36fluc þ -expressing subcutaneous gliomas revealed peak Rluc activity 36 h after intratumoral injection as determined by coelenterazine injection followed by imaging. TRAIL-treated gliomas regressed in size over a period of 4 weeks as compared to the mock-injected gliomas. These results show the efficacy of vector delivered TRAIL in treating tumors in vivo and offer a unique way to monitor both gene delivery and efficacy of TRAIL-induced apoptosis in tumors in vivo in real time by dual enzyme substrate (Rluc/Fluc) imaging.
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has been shown to induce apoptosis in neoplastic cells. While many previous studies have been performed in cell culture, the delivery and efficiency of TRAIL variants in vivo is less well established. Using dual substrate/ reporter bioluminescence imaging (Fluc: firefly luciferase -luciferin and Rluc: Renilla luciferase -coelenterazine), we tested the efficacy of TRAIL using replicationdeficient herpes simplex virus (HSV) type 1 amplicon vectors in gliomas. The cDNA for complete TRAIL and the extracellular domain of TRAIL (aa 114-281) were cloned into HSV amplicons and packaged into helper virus-free vectors. Both forms of TRAIL induced similar degrees of apoptosis in human glioma cells (Gli36) in culture within 24 h of infection with TRAIL amplicon vectors. Growth of tumors stably transfected with Fluc (Gli36fluc þ ) was readily monitored in vivo by bioluminescence imaging following luciferin administration. HSV amplicon vectors bearing the genes for TRAIL and Rluc injected directly into Gli36fluc þ -expressing subcutaneous gliomas revealed peak Rluc activity 36 h after intratumoral injection as determined by coelenterazine injection followed by imaging. TRAIL-treated gliomas regressedIntroduction Cells die by one of two pathways: necrosis or programmed cell death/apoptosis. Apoptosis is seen during tumor regression (Vaux, 1993) and can be triggered through therapeutic transgene expression (Pulkkanen et al., 2001) , viral infection (Shen and Shenk, 1995) , growth factor withdrawal (Evan et al., 1995) , and/or DNA damage (Evan and Littlewood, 1998) . Many therapeutic proteins used to kill tumor cells do so by binding to cell-surface receptors and triggering apoptosis. The proteins of the tumor necrosis family, TNF-a, Fas ligand (FasL), and tumor necrosis-related apoptosis-inducing ligand (TRAIL) are type II transmembrane proteins that function by interacting with, and thus activating, their respective cell-surface receptors, leading to cell death (Nagata, 1997; Ashkenazi and Dixit, 1998; Wajant et al., 2002, LeBlanc and Ashkenazi, 2003) . Like most of the TNF family ligands, TRAIL, upon cleavage by specific proteases, forms soluble heterotrimeric molecules (Gruss and Dower, 1995) and various studies have shown that a truncated soluble form of TRAIL protein produced in different expression systems has potent apoptosis-inducing activity Pitti et al., 1996) .
TRAIL can induce apoptosis in tumor cells of diverse origins, both in culture and in vivo, while sparing most normal cells (Rieger et al., 1998) . Concerns have been raised about TRAIL toxicity in humans, with reports revealing the adverse effects of TRAIL on primary cultures of human hepatocytes and brain tissue (Jo et al., 2000; Nitsch et al., 2000) . It has now been confirmed that different recombinant versions of TRAIL protein used in these studies have a wide variability in their potential for toxicity. For example, the Apo2L/ TRAIL.0 did not induce apoptosis in human hepatocytes or adverse effects in the brain in two primate models (Lawrence et al., 2001; Voelkel-Johnson et al., 2002) . Various studies have shown the antitumor effects of TRAIL following the systemic administration of soluble TRAIL protein alone or in combination with chemotherapeutic agents like 5-fluorouracil and ionizing radiation (Ashkenazi and Dixit, 1999; Walczak et al., 1999a, b; Chinnaiyan et al., 2000) . However, the requirement of large amounts of TRAIL and the short half-life of TRAIL are the major hindrances of such a treatment paradigm.
The employment of various gene delivery systems, such as viral vectors, has made it possible to administer therapeutic genes directly into tumor sites in vivo. The use of replication-competent adenoviruses for the intratumoral delivery TRAIL has been shown to have antitumor activity (Griffith et al., 2000; Kagawa et al., 2001) . Replication-deficient HSV-derived amplicon vectors, used in this study, offer many advantages for gene delivery including high efficiency of infection of many cell types, in both dividing and nondividing states, large transgene capacity and low inherent toxicity (Fraefel et al., 2000) . However, the paucity of noninvasive imaging methods to monitor gene delivery, the specificity and duration of transgene expression, and tumor cell death using viral vectors in vivo has been one of the main limitations for testing the efficacy of this new treatment paradigm.
Several approaches to imaging gene delivery and expression have been described Contag and Buchmann, 2002; Gambhir, 2002; Tjuvajev et al., 2002; Weissleder, 2002) . Here we used bioluminescent imaging because of its capacity for dual reporters, ready application to mouse imaging, and simplicity. In addition, characteristics like low background luminescence from normal tissue and the rapid turnover of luciferase substrates make this method suited for temporal in vivo imaging of gene expression. Luciferases comprise a family of photoproteins derived from fireflies, coelenterates, and bacteria. Eucaryotic luciferases Fluc and Rluc genes from firefly (Photinus) and the sea pansy (Renilla reniformis), respectively, are distinct in terms of substrate requirements and can thus be used for sequential differential imaging in the same living animal (Bhumik and Gambhir, 2002) . This dual imaging approach has the potential to evaluate gene delivery and expression in tumors in vivo, and to monitor changes in tumor volume caused by apoptotic and other therapeutic genes.
The goal of the current study was to determine the therapeutic efficacy of herpes simplex virus (HSV) amplicon vectors encoding TRAIL and extracellular domain of TRAIL and to image protein expression and therapeutic efficacy by dual enzyme substrate (Rluc/ Fluc) bioluminescence imaging. Our results show that HSV amplicon vectors containing either the membranebound or engineered secreted form of TRAIL can induce apoptosis in glioma cells in culture and that the membrane-bound form can reduce glioma volumes in mice by repeated injections over a period of 1 month. Furthermore, we have shown that amplicon vector gene delivery and efficacy of TRAIL-induced apoptosis in experimental brain tumors in vivo can be visualized in real time by dual enzyme substrate (Rluc/Fluc) imaging.
Results
This study explores the therapeutic potential of TRAIL delivered by HSV-amplicon vectors on glioma tumors. TRAIL cDNA (A-TRAIL) and its N-terminal GFP fusion (A-GFP-TRAIL) were cloned into HSV amplicons and packaged into HSV virions (Figure 1a) . To explore the potential of the soluble form of TRAIL in our system, we fused an epidermal growth factor receptor (EGFR) secretable signal (Ss) sequence to aa 114-281 of TRAIL and to the N-terminal GFP-aa 114 TRAIL fusion. The transgenes were also cloned into HSV amplicon and packaged into HSV virions, resulting in A-Ss-TRAIL and A-SsGFP-TRAIL vectors, respectively ( Figure 1a ). All four packaged TRAIL vectors had a very high infectivity for human glioma Gli36 cells, as shown in Figure 1b . To determine the expression of TRAIL protein, cells were infected with A-TRAIL vector and 48 h later, the total protein was isolated, fractionated by denaturing SDS-PAGE and (Figure 1d , e). In addition, TRAIL protein was detected in the medium of both A-TRAILand A-Ss-TRAIL-infected cells with minimal background in the noninfected cells ( Figure 1f ). These results show that the N-terminal GFP fusion alters the localization of the full-length TRAIL and reveal that both TRAIL and Ss-TRAIL proteins are secreted from the cells. Viability assays (WST) were used to quantitate the effect of TRAIL on Gli36 cells. Cells were infected with A-TRAIL-, A-Ss114TRAIL-or control-amplicon vectors at an MOI ¼ 1. WST assays performed 24 h postinfection revealed TRAIL-induced apoptosis in about 90-95% of the infected Gli36 cells. The truncated 114-281 TRAIL had an almost equivalent effect on cell killing as the full-length TRAIL protein when cells were near confluency (Figure 2a ). Morphological studies using TUNEL and 4-6-diamino-2-phenylindole (DAPI) nuclear staining 12 h after A-TRAIL vector infection revealed nuclear fragmentation (a hallmark of apoptosis) in cells infected with A-TRAIL, but not in the A-HGCX control vector-infected cells (Figure 2b ). Immunoblotting of the total protein from TRAIL-infected and noninfected cells showed the activation of proteins specific for TNF family of ligand-induced apoptosis. Immunoblot analysis with the anticaspase-9 antibody showed the presence of the 37 kDa cleaved caspase-9 in the TRAIL-expressing cells and not in the noninfected cells (Figure 2c) . Similarly, immunoblotting with the anticleaved PARP antibody showed the presence of 89 kDa cleaved PARP fragment specifically in the TRAIL-expressing cells. Together, these results demonstrate that administration of both the full-length and truncated TRAIL via HSV amplicon vectors effectively elicits apoptosis in cultured glioma cells. As both versions of TRAIL have similar apoptotic effects, we decided to use full-length TRAIL HSV-amplicon vector for subsequent studies.
The cDNAs for Fluc and Rluc were cloned into amplicons ( Figure 3a ) and packaged as described Gli36fluc þ cells were then implanted into the flanks of nude mice. Tumors were typically detectable by bioluminescence imaging 7-10 days after implantation of 5 Â 10 6 Gli36fluc þ cells (Figure 4a ). In order to determine the distribution of gene delivery by HSVamplicon vectors injected into these tumors, 20 ml of A-Rluc-amplicon vector (2.3 Â 10 8 transducing unit (TU)/ml) was injected into each tumor and Rluc activity was imaged 36 h later. The total tumor area of the A-Rluc injected glioma was determined by imaging the same mice for Fluc activity (Figure 4a ). The expression of Rluc by cells infected with the A-Rluc in the same tumor is shown (Figure 4b ).
Sections of Gli36fluc
þ tumors assessed histologically by hematoxylin and eosin (H&E) staining and by GFP fluorescence verified the infection of tumor cells by the vector (Figure 4c ). These results show that genes delivered by HSV-amplicon vectors in vivo are expressed in a substantial number of tumor cells and that dual substrate/reporter bioluminescence imaging can be used to determine simultaneously the amplicon vector delivery and the tumor volumes in vivo.
In order to monitor the effect of the TRAIL-amplicon vector on Gli36fluc þ gliomas in vivo, correlation studies were performed between the number of Gli36fluc þ cells in vivo and the subsequent number of photons emitted. Different concentrations of Gli36fluc þ cells (ranging from 1 Â 10 5 to 1 Â 10 7 ) were implanted subcutaneously and mice were imaged for Fluc activity 2 h later. The bioluminescent signal was linearly correlated to the number of implanted Gli36fluc þ cells, with a correlation coefficient factor of 0.98 (Figure 5a ). To document the therapeutic effect of TRAIL-amplicon vector in vivo, animals bearing flank Gli36fluc þ gliomas were randomly assigned into different groups and injected intratumorally with A-TRAIL-amplicon vector, empty amplicon vector, replication conditional hrR3 virus, or left untreated. Animals were injected with the vector/ virus every 4 days and imaged for luciferase photon count every 7 days for a maximum period of 1 month. The results from four representative mice are shown in Figure 5b . Tumors left untreated showed continuous growth, increasing in volume 10-12-fold during the 1 month observation period. The animals treated with replication-competent hrR3 virus that has been previously shown to have oncolytic properties, showed a complete regression of tumors after the second week of the first treatment. All the tumors injected with A-TRAIL-amplicon vector demonstrated a slight growth initially, but regressed gradually from the 14th day onwards, throughout the treatment period (Figure 5b,  c) . Most of the TRAIL-treated tumors had undergone complete regression at the end of the treatment period ( Figure 5 ). These results show that HSV-amplicon vectors containing TRAIL reduces glioma volumes in mice, which are monitored real time with bioluminescence imaging. 
Materials and methods

Generation of TRAIL and RLuc HSV amplicons
Amplicons, pHGCX bearing an expression cassette for enhanced green fluorescent protein (eGFP) (from Dr Yoshimura Saeki, MGH), and pKSR2, derived from it to express the red fluorescent protein (DsRed2) instead of eGFP, both under IE4/5 promoter, were used as the plasmid backbones. The cDNA sequence encoding the TRAIL was amplified by polymerase chain reaction (PCR) using the pORF-TRAIL vector (Invivogen, San Diego, CA, USA) as a template. Primer HindII1 TRAILf (5 0 GCGCAAGCTTATGGCTATGATGG-AGGTC CAG3 0 ) and primer BamHITRAILr (5 0 CGCGGAT-CCTTAGCCAACTAAAAAGGCCCC3 0 ) amplified a PCR fragment of 0.84 kb that was cloned into the multiple cloning site of pKSR2 following digestion with HindIII and BamHI, resulting in a full-length pA-TRAIL construct. To create an Nterminal eGFP fusion protein of TRAIL, the cDNA for TRAIL was amplified by PCR using primers NheITRAILf (5 0 CTAGCTAGCATGGCTATGATTTAGCCAACTAAAA-GG3 0 ) and HindIIITRAILr (5 0 CGCCAAGCTTGCCAACTT-AAAAAGGCCCC3 0 ). The cDNA sequence encoding the eGFP was amplified from pEGFP (Clontech, Palo Alto, CA, USA) by PCR using the primers HindII1f (5 0 TCCCCGGGT-ATTTTCTTCGATGTCCCTG3 0 ) and XhoIr (5 0 ATAAGAA-TGCGGCCGCCCTTGGACCAGATA3 0 ). The resulting 0.84 kb TRAIL fragment was digested with NheI and HindIII and ligated in-frame together with a HindIII/XhoI digested 0.7 kb eGFP fragment into NheI/XhoI digested pKSR2. This resulted in the pA-GFP-TRAIL construct. For creating the secretable form of TRAIL, the cDNA sequence encoding EGFR secretable signal sequence was amplified from de 2-7 EGFR (a gift from Drs Huang and Cavenee, University of California, San Diego, CA, USA) by PCR using the primers Nhe1EGFRf (5 0 CTAGCTAGCATGCGACCCTCCGGGACG3 0 ) and HindEGFRr (5 0 CGCGAAGCTTAACTTTCTTTTCCTCCA-GAGCCCGACTCGC3 0 ). The cDNA sequence encoding the aa 114-281 of TRAIL was amplified by PCR using the pORF-TRAIL vector (Invivogen, San Diego, CA, USA) as a template using primers HindII1TRAILf (5 0 CGCGAAGCTTGTGAG-AGAAAGAGGTCCTCAGAGA3 0 ) and BamHITRAILr. The resulting 0.52 kb fragment was digested with HindIII and BamHI and ligated in-frame with the 60 bp NheI/ HindIII digested signal sequence fragment into the NheI/ BamHI digested pKSR2 resulting in the pA-SsTRAIL construct. To create an N-terminal eGFP fusion protein of Ss-TRAIL, the cDNA sequence encoding eGFP was amplified by PCR using the primers HindII1f (5 0 TCCCCGGGTAT-TTTCTTCGATGTCCCTG3 0 ) and HindIIIr. The resulting 0.7 kb eGFP fragment was digested withHindIII and ligated into the HindIII digested A-Ss-TRAIL construct, resulting in the pA-Ss-GFPTRAIL construct. To generate a Rluc Imaging TRAIL-induced apoptosis in vivo K Shah et al amplicon plasmid, pA-Rluc, plasmid phrl-CMV (Promega) was digested with NheI and BamHI and the 2.2 kb cDNA fragment encoding Renilla luciferase was isolated and cloned following the CMV promoter into NheI and BamHI sites of pHGCX amplicon. To construct Fluc amplicon plasmid pAFluc, the pGL3Basic plasmid (Promega) was digested with HindIII and BamHI and a 1.9 kb cDNA fragment encoding Fluc was isolated and cloned into HindIII and BamHI sites in pHGCX.
All amplicon plasmid constructs were packaged as HSVamplicon vectors by using a helper virus-free packaging system (Saeki et al., 2001) . Amplicon vector stocks were harvested 60 h later, freeze-thawn three times, sonicated, and purified by brief centrifugation at 1000 g for 10 min. Amplicon titers, TU/ ml, were determined by infecting 3 Â 10 5 293T/17 cells/well in 24-well plates and then counting the GFP-or RFP-positive cells at Â 10 magnification 18 h postinfection.
Cell lines and cell culture
Gli36 human primary glioma cells provided by Dr Anthony Capanogni (UCLA, CA, USA; Kashima et al., 1995) were stably cotransfected with pA-Fluc plasmid and pBabePuro plasmid (containing the gene for puromycin resistance; Morgenstern and Land, 1990) using lipofectamine transfection reagent (Invitrogen, Carlsbad, CA, USA). The resulting Flucpositive clones selected using 1 mg/ml of puromycin in the growth medium were isolated and checked for luciferase activity, as described below. The clone showing the highest luciferase activity, Gli36fluc þ , was used for these studies.
SDS-PAGE and Western blotting
Cells were lysed 24 h after infection in a buffer containing 50 mm Tris (pH 8.0), 150 mm NaCl, 1% NP-40, supplemented with single strength proteinase inhibitor (Complete-Mini cocktail; Boehringer-Mannheim, Germany; Indianapolis, IN, USA) and centrifuged at 40 000 g for 30 min at 41C. Equal amounts of total cell protein (30 mg) were denatured and separated by SDS-PAGE and transferred to nitrocellulose membrane (IMMOBILON) in a transfer buffer (25 mm Tris, 192 mm glycine, pH 8.3) using a Bio-Rad Transblot Cell for 1 h at 0.5 mA at 41C. The membranes were washed in TBS-T buffer (10 mm Tris-HCl, pH 7.5, 150 mm NaCl, 0.05% Tween-20) and blocked with 10% nonfat dried milk in TBS-T for 3 h at room temperature, washed with TBS-T and incubated with either of the following antibodies: anti-rabbit TRAIL antibody (Abcam Ltd, Cambridge, UK); anti-rabbit cleaved caspase-9 antibody; or anti-rabbit cleaved-PARP (poly(ADP ribose) polymerase) antibody (Cell Signaling, Beverly, MA, USA) for 1 h at room temperature. After three washes in TBS-T, membranes were incubated for 1 h with anti-goat immunoglobulin G peroxidase-conjugated secondary antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) in TBS-T. After washings, as described above, the blots were developed by using enhanced chemiluminescence reagents (Amersham, Piscataway, NJ, USA). Membranes were then exposed to film for 30 s to 30 min.
Cell viability assays and ELISA
Gli36 cells (0.2 Â 10 6 ) were infected with either A-TRAIL, ASsTRAIL, or control A-HGCX amplicon vectors in a 24-well plate at multiplicity of infection (MOI) of 1 TU/cell, and 12 h later, amplicons were removed and cells incubated with 250 ml of fresh medium. At 24 h after infection, the medium was collected and used for TRAIL protein determination as described below. The infected cells were detached and replated at a concentration of 1 Â 10 4 cells/well in 96-well Primaria plates (Falcon, Bedford, MA, USA). After 2 h, WST (tetrazolium salt) assays (Roche, Indianapolis, IN, USA) were performed in triplicate by adding 10 ml of WST reagent/well. Plates were read at an absorbance of 450 nm, 2 h after the addition of WST reagent using a V max kinetic microplate reader (Molecular Devices, Sunnyvale, CA, USA). Background absorbance was subtracted using the control media and the WST reagent.
TRAIL protein concentration in the medium collected from A-TRAIL-, A-Ss-TRAIL-infected Gli36 cells, or control A-HGCX cells was measured with the TRAIL Immunoassay Kit (Biosource International, Camarillo, CA, USA) according to the manufacturer's protocol using recombinant hTRAIL expressed in Escherichia. coli as a standard. The assay used coated human TRAIL monoclonal antibody and soluble biotinylated TRAIL polyclonal antibody. Plates were read at 450 nm by an absorbance plate reader (Molecular Devices, Sunnyvale, CA, USA) and the data were analysed by SOFT-MAX.
Immunocytochemistry
At 12 h after plating Gli36 cells or Gli36fluc þ cells in a 24-well plate, the cells were washed with PBS and fixed in 4% paraformaldehyde for 20 min at room temperature (RT). The cells were then washed with PBS and permeabilized in PBS plus 0.1% Triton X-100 for 20 min at RT. Cells were then blocked in PBS plus 1% BSA for 1 h and then incubated with a goat antiluciferase antibody (Molecular Probes, Eugene, OR, USA) for 1 h, washed with PBS and then incubated with an anti-goat Alexa dye-conjugated secondary antibody (Molecular Probes, Eugene, OR, USA) for 1 h. After hybridization and subsequent washing with PBS, the cells were mounted and microscopy was performed.
For TUNEL staining, Gli36 cells on coverslips were infected with A-TRAIL vector at MOI ¼ 1, washed, fixed, and permeabilized as above and 24 h later, incubated with terminal transferase (TdT) buffer (in 30 mm Tris, 140 mm sodium cacodylate, 1 mm cobalt chloride, pH 7.2) containing TdT (0.5 U/ml) and biotin-16-deoxyUTP (dUTP) (0.04 mol/l) (all reagents from Boehringer-Mannheim, Germany; Indianapolis, IN, USA) for 1 h at 371C. The reaction was terminated by washing with PBS. Biotin-16-dUTP incorporated into the cells was reacted with streptavidin-Cy5 (Jackson Immuno Research) for 5 min for immunofluorescence microscopy. After washing in PBS, cells were incubated with DAPI (4-6-diamino-2-phenylindole), washed with PBS and coverslipped with mounting medium (Fisher Scientific, Pittsburgh, PA, USA).
Tumor model and amplicon treatments
Gli36fluc
þ tumor cells in mid-log phase were harvested by trypsinization, and single-cell suspensions of 5 Â 10 6 cells in 0.75 ml DMEM were mixed with an equal amount of Matrigel (BD Biosciences) and then injected subcutaneously into the flanks of 4-to 5-week-old nude mice. After 5-7 days, when tumors could have grown to 2-7 mm diameter, mice received either repeated intratumoral injections of 20 ml A-TRAIL vector (2.5 Â 10 8 TU/ml) or control-amplicon vector, A-HGCX (2.6 Â 10 8 TU/ml), or replication conditional hrR3-HSV virus (1.2 Â 10 8 TU/ml) in a total volume of 20 ml, with intratumoral manipulation of the needle to ensure spread of virus. To monitor the changes in tumor volume, mice bearing Gli36fluc þ tumors were injected with TRAIL-and control-amplicon vectors every 4 days and imaged every 7 days for a period of 1 month as described below. Animals bearing tumors were then killed by intracardiac prefusion with 10 mm sodium phosphate buffer, pH ¼ 7.3, followed by 4% paraformaldehyde in PBS. Tumors were removed and sectioned on a sledge microtome (10 mm slices).
Luciferase activity assays A total of 3 Â 10 5 Gli36 cells or Gli36fluc þ cells were seeded in 24-well plates 12 h before Fluc activity measurements. Cells were incubated with 150 mg/ml dluciferin and assayed for luciferase activity using liquid nitrogen charged cooled device (CCD) (Roper Scientific, Trenton, NJ, USA). To assess the luciferase activity of cells expressing Rluc, cells were infected with Rluc-amplicon vector at an MOI of 0.5 to achieve 80-90% infection of cells, as assessed by GFP fluorescence. At 48 h postinfection, cells were incubated with 10 mg/ml of coelenterazine (Biotium, Inc, Hayward, CA, USA) and the photon count measured, as above.
In vivo optical imaging of luciferase expression by using a cooled CCD camera Mice bearing flank tumors were imaged for Fluc or Rluc activity using a cryogenically cooled high efficiency CCD camera system (Roper Scientific, Trenton, NJ, USA). Mice were given an intraperitoneal (i.p.) injection of 150 ml d-luciferin (Biotium, Inc., Hayward, CA, USA, 150 mg/g body weight) and images were acquired 5-10 min after d-luciferin administration following an initial optimization study. A light image of the animal was taken in the chamber using dim polychromatic illumination. The spatial distribution of luciferase activity within the tumors was then measured by recording photon counts in the CCD with no illumination. Following data acquisition, postprocessing and visualization was performed using a in house program, CMIRImage, using image display and analysis suite developed in IDL (Research Systems Inc., Boulder, CO, USA). Regions of interest were defined using an automatic intensity contour procedure to identify bioluminescence signals with intensities significantly greater than the background. The mean, standard deviation, and sum of the photon counts in these regions were then calculated. For visualization purposes, bioluminescence images were fused with the corresponding white light surface images in a transparent pseudocolor overlay, permitting correlation of areas of bioluminescent activity with anatomy.
For in vivo correlation studies, different concentrations of Gli36fluc þ cells (ranging from 1 Â 10 5 to 1 Â 10 7 ) were implanted subcutaneously and mice were imaged for Fluc activity 2 h later, as above. To assess the delivery of HSVamplicon vectors into gliomas, Gli36fluc þ tumor-bearing nude mice were injected with Rluc-amplicon vector (1 Â 10 6 TU in 20 ml) directly into the tumors and mice were imaged 36 h later immediately after injection of 150 ml (100 mg/animal) coelenterazine (Biotium, Inc. Hayward, CA, USA) into the tail vein.
Discussion
This study demonstrates the in vivo efficacy of TRAIL-induced antitumor effects using replication-deficient HSV-amplicon vectors and imaging transgene delivery and TRAIL-induced antitumor effects by dual luciferase/substrate (Renilla/coelenterazine, firefly/luciferase) bioluminescence imaging. Both TRAIL or the secreted form of TRAIL (soluble TRAIL) induces apoptosis in glioma cells in culture and the former was shown to reduce tumor volumes in mice bearing gliomas over a period of 1 month as detected by imaging of Fluc-expressing glioma cells.
Although the other members of TNF family, TNF-a and FasL, have potent cytotoxic activity against many tumor cell types, the use of these death ligands for cancer therapy has been limited by their severe toxicity to normal tissues (Ashkenazi and Dixit, 1999) . Owing to its potential to kill tumor cells specifically TRAIL has become an attractive molecule for the treatment of cancers (Ashkenazi and Dixit, 1999; Walczak et al., 1999a, b) . Studies with recombinant TRAIL have revealed that the extracellular domain of TRAIL, soluble TRAIL, also has a high degree of potency and bystander effect for tumors experimentally (Ashkenazi and Dixit, 1999; Gliniak and Le, 1999; Walczak et al., 1999a, b; Chinnaiyan et al., 2000) . One of the problems with the use of TRAIL in vivo has been to sustain high local concentrations within the tumor (Walczak et al., 1999a, b) . Localized delivery with TRAIL viral vectors provides a means to maintain high concentrations of TRAIL protein within the tumor with few treatments (Griffith and Broghammer, 2001 ). Our results show that both soluble TRAIL and membrane-bound TRAIL delivered to the glioma cells by HSV-amplicon vectors have a similar effect on cell killing. Recombinant HSV vectors, for example, deleted for ribonucleotide reductase, (hrR3) have been shown previously to replicate preferentially in and kill tumor cells (Boviatsis et al., 1994; Fulci and Chiocca, 2003) . The safety of oncolytic viral therapy depends on the selectivity of viral replication in dividing cell as compared to postmitotic brain cells. There are two potential problems with the use of such replication-conditional oncolytic virus vectors. First, actively dividing cell populations in the body other than tumor cells may be susceptible, especially in immune-compromised cancer patients. Second, these vectors are most effective against actively dividing cells, while in brain tumors most cells are in G 0 in any given treatment window (Di et al., 1997) . In contrast, HSV-amplicon vectors do not express any viral genes, depending on the helper functions for replication and packaging and thus have low to no toxicity, combined with highly efficient gene delivery and large transgene capacity. We have used HSV-amplicon vectors in these studies and shown that those encoding TRAIL can be efficiently delivered into tumors and substantial levels of tumor regression can be attained. However, the use of noninvasive imaging methods to monitor viral gene delivery in vivo has been one of the main limitations for testing the efficacy of the viral gene therapy paradigms. In these studies, we have shown that dual luciferase/substrate (Renilla/coelenterazine, firefly/luciferase) bioluminescence imaging has the potential to be used to monitor both transgene delivery and therapeutic antitumor effects.
The recent developments in bioluminescence imaging systems allow measurement of tumor volumes in living animals. Rapid and noninvasive measurements can be obtained before, during, and after treatments (Contag et al., 1998) , and these quantitative measurements correlate well with the actual tumor volume determined by histochemical correlation, depending on the location of tumors . Since bioluminescence imaging in vivo only measures luciferase activity in live cells, due to the requirement for O 2 and ATP to catalyze light from the substrate, luciferin, this method is particularly useful for monitoring the death of tumor cells, as opposed to other techniques, such as MRI, which measure total tumor volume including necrotic areas. These necrotic areas are unable to emit photons after luciferasesubstrate administration. Also, in contrast to the conventional imaging approaches, which mostly provide end point data, bioluminescence imaging permits temporal and spatial information throughout an entire experiment by acquiring consecutive images from the same animals. In addition, the unique substrates of Rluc and Fluc provide a basis for sequential imaging of both in the same living animal (Bhaumik and Gambhir, 2002) . Rluc activity peaks within 1 min and is undetectable by 10 min after intravenous injection of coelenterazine, whereas light from Fluc is maximal at 3-4 min and declines slowly over 30 min (Luker et al., 2002) . There was no significant Fluc bioluminescence when mice bearing Flucexpressing gliomas were injected with coelenterazine and similarly, no Rluc bioluminescence was detected when mice were given d-luciferin injections after the intratumoral injection of A-Rluc-amplicon vector, thus showing the potential of dual luciferase imaging in experimental gene therapy of cancer.
The paucity of using tumor-specific apoptotic genes and noninvasive imaging methods to monitor gene delivery and expression in vivo has been one of the main limitations to the development of cancer therapy using viral vectors. We have shown that TRAIL induces apoptosis in vivo and the gene delivery can be monitored noninvasively using the Rlucexpressing HSV-amplicon vectors. The engineering of new secretable forms of TRAIL that induce higher degree of apoptosis and, the use of multiple in vivo fluorescent imaging agents to allow real-time, multidimensional assessment of tumor therapy will be highly useful in broadening the scope of analyses that can be performed.
